Natera agreed to acquire Foresight Diagnostics for $275 million upfront plus up to $175 million in milestone earnouts to integrate Foresight’s PhasED-Seq phased-variant ctDNA technology into Natera’s Signatera MRD platform. The deal aims to raise sensitivity for minimal residual disease detection and expand Natera’s commercial footprint in lymphoma and other solid tumors. Natera says the acquisition will enable immediate research-use integration and accelerate a clinical launch in 2026. Analysts flagged that phased-variant detection could materially lift assay sensitivity and open new clinical use-cases, particularly in B-cell lymphomas where Foresight already has clinical momentum. The transaction is positioned as strategic M&A to combine Natera’s commercial scale with Foresight’s technical differentiation, with potential near-term revenue upside tied to reimbursement progress and guideline adoption.